文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

供者克隆性造血在异基因造血干细胞移植中的作用

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.
PubMed 文献 · J Clin Oncol · 2018-11-07

该研究对500例年龄≥55岁的健康亲缘供者进行66基因靶向测序,发现80例(16.0%)存在CHIP。供者CHIP与受者慢性GVHD累积发生率升高(HR 1.73)及复发/进展累积发生率降低(多因素HR 0.63)相关,但总生存无影响(HR 0.88)。作者认为老年亲缘供者伴CHIP的移植似乎安全且生存相似。

要点

  • 500例亲缘供者中80例(16.0%)检出CHIP,中位变异等位基因频率5.9%。
  • 供者CHIP与受者cGVHD风险升高相关(HR 1.73,95%CI 1.21-2.49,P=.003)。
  • 供者CHIP与受者CIR/P降低相关(多因素HR 0.63,95%CI 0.41-0.98,P=.042),OS无影响。

核心结论

  • 老年亲缘供者伴CHIP的异基因HSCT似乎安全且生存相似。
  • 需在年轻及无关供者中进一步研究以扩展结果。
  • 需验证性研究和机制实验以检验供者CHIP可能促进cGVHD并降低复发/进展风险的假说。

研究设计与样本

  • 收集500例健康亲缘HSCT供者(年龄≥55岁)干细胞捐献时的血样,进行66基因靶向测序。
  • 评估供者CHIP对受者结局的影响,包括GVHD、复发/进展累积发生率(CIR/P)和总生存(OS)。

主要发现

  • 500例供者中80例(16.0%)检出92个克隆性突变,中位变异等位基因频率5.9%。
  • 与髓系恶性肿瘤患者相关的供者CHIP患病率高于与淋系恶性肿瘤相关的供者(19.2% vs 6.3%;P≤.001)。
  • 受者接受供者CHIP移植后cGVHD累积发生率升高(HR 1.73;95%CI 1.21-2.49;P=.003)。
  • 受者接受供者CHIP移植后CIR/P降低(单因素:HR 0.62;95%CI 0.40-0.97;P=.027;多因素:HR 0.63;95%CI 0.41-0.98;P=.042),非复发死亡无影响。
  • 25个突变的连续定量显示24/25个克隆植入,其中半数出现不成比例扩增;两例受者发生供者细胞白血病;OS未受供者CHIP状态影响(HR 0.88;95%CI 0.65-1.321;P=.434)。

临床怎么用

  • 作者认为,在老年亲缘供者背景下,使用伴CHIP的供者进行异基因HSCT似乎安全且生存相似。

局限性

  • 需在年轻及无关供者中进一步研究以扩展结果。
  • 需验证性研究和机制实验以检验供者CHIP可能促进cGVHD并降低复发/进展风险的假说。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clonal hematopoiesis of indeterminate potential (CHIP) occurs in the blood of approximately 20% of older persons. CHIP is linked to an increased risk of hematologic malignancies and of all-cause mortality; thus, the eligibility of stem-cell donors with CHIP is questionable. We comprehensively investigated how donor CHIP affects outcome of allogeneic hematopoietic stem-cell transplantation (HSCT). METHODS: We collected blood samples from 500 healthy, related HSCT donors (age ≥ 55 years) at the time of stem-cell donation for targeted sequencing with a 66-gene panel. The effect of donor CHIP was assessed on recipient outcomes, including graft-versus-host disease (GVHD), cumulative incidence of relapse/progression (CIR/P), and overall survival (OS). RESULTS: A total of 92 clonal mutations with a median variant allele frequency of 5.9% were identified in 80 (16.0%) of 500 donors. CHIP prevalence was higher in donors related to patients with myeloid compared with lymphoid malignancies (19.2% v 6.3%; P ≤ .001). In recipients allografted with donor CHIP, we found a high cumulative incidence of chronic GVHD (cGVHD; hazard ratio [HR], 1.73; 95% CI, 1.21 to 2.49; P = .003) and lower CIR/P (univariate: HR, 0.62; 95% CI, 0.40 to 0.97; P = .027; multivariate: HR, 0.63; 95% CI, 0.41 to 0.98; P = .042) but no effect on nonrelapse mortality. Serial quantification of 25 mutations showed engraftment of 24 of 25 clones and disproportionate expansion in half of them. Donor-cell leukemia was observed in two recipients. OS was not affected by donor CHIP status (HR, 0.88; 95% CI, 0.65 to 1.321; P = .434). CONCLUSION: Allogeneic HSCT from donors with CHIP seems safe and results in similar survival in the setting of older, related donors. Future studies in younger and unrelated donors are warranted to extend these results. Confirmatory studies and mechanistic experiments are warranted to challenge the hypothesis that donor CHIP might foster cGVHD development and reduce relapse/progression risk.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Frick M, Chan W, Arends CM, et al. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2018. PMID: 30403573. doi:10.1200/JCO.2018.79.2184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。